Inicio>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Acetyltransferases>>YF-2

YF-2

Catalog No.GC31099

YF-2 es un activador de acetiltransferasa de histona permeable a la barrera hematoencefÁlica altamente selectivo, acetila H3 en el hipocampo, con EC50 de 2,75 μM, 29,04 μM y 49,31 μM para CBP, PCAF y GCN5, respectivamente, no muestra ningÚn efecto sobre HDAC .

Products are for research use only. Not for human use. We do not sell to patients.

YF-2 Chemical Structure

Cas No.: 1311423-89-8

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
149,00 $
Disponible
5mg
135,00 $
Disponible
10mg
216,00 $
Disponible
50mg
765,00 $
Disponible
100mg
1.350,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease[1].

YF-2 (0.03, 0.1, 0.25, 0.5, 1, 2.5, 5, 15, 40 and 80 μM, 72 hours) inhibits the preliferation of U251, CCRF-CEM, Hs578T, NCI-ADR-RES cells[1].

YF-2 (20 mg/kg, 2 hours befor electric shock or 5 mg/kg, 30 min before the electric shock, i.p.) rescues the defect in contextual memory in mice, and shows no effect on contextual memory alone at 20 mg/kg in mice[1].

[1]. FENG, Yen, et al. HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF. WO 2011072243A1.

Reseñas

Review for YF-2

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for YF-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.